Thl7 cells In Behçet's disease: A new immunoregulatory axis

Clinical and Experimental Rheumatology

Volumn 29, Issue 4 SUPPL. 67, 2011, Pages

  Hamzaoui, K ^a  

^a UNIVERSITY OF TUNIS EL MANAR   (Tunisia)

Author keywords

Beh et's disease; FOXP3; RORC; Thelper; Transcription factors

Indexed keywords

CHEMOKINE RECEPTOR CCR6; CXCL3 CHEMOKINE; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 6; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; TRANSCRIPTION FACTOR FOXP3; CYTOKINE; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET;

BEHCET DISEASE; CD4+ T LYMPHOCYTE; CELL ACTIVITY; CELL INTERACTION; CELL MIGRATION; IMMUNOREGULATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE; TH1 CELL; TH17 CELL; TH2 CELL; HUMAN; IMMUNOLOGY; IMMUNOMODULATION; ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; CELLS BY BODY ANATOMY; CYTOKINE PRODUCTION; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; INNATE IMMUNITY; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

BEHCET SYNDROME; HUMANS; IMMUNOMODULATION; TH17 CELLS;

EID: 80855144043     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Review

References (57)

1. CHI W, YANG P, ZHU X et al.: Production of interleukin-17 in Behçet's disease is inhibited by cyclosporin A. Mol Vis 2010; 16: 880-6.
2. KAPSIMALI VD, KANAKIS MA, VAIOPOULOS GA, KAKLAMANIS PG: Etiopathogenesis of Behçet's disease with emphasis on the role of immunological aberrations. Clin Rheumatol 2010; 29: 1211-6.
3. HAMZAOUI K, MAtTRE B, HAMZAOUI A: Elevated levels of MMP-9 and TIMP-1 in the cerebrospinal fluid of neuro-Behçet's disease. Clin Exp Rheumatol 2009; 27 (Suppl. 53): S52
4. HAMZAOUI K, KARRAY E, SASSI FH, HAMZAOUI A: Vitamin D modulates peripheral immunity in patients with Behçet's disease. Clin Exp Rheumatol 2010; 28 (Suppl. 60): S50-7.
5. KIM J, PARK JA, LEE EY, LEE YJ, SONG YW, LEE EB: Imbalance of Thl7 to Thl cells in Behçet's disease. Clin Exp Rheumatol 2010; 28 (Suppl. 60): S16-9.
6. PAY S, SIMSEK I, ERDEM H, DINC A: Immunopathogenesis of Behçet's disease with special emphasize on the possible role of antigen presenting cells. Rheumatol Int 2007; 27: 417-24. (Pubitemid 46294993)
7. FERRANTE A, CICCIA F, PRINCIPATO A et al.: A Thl but not a Thl7 response is present in the gastrointestinal involvement of Behçet's disease. Clin Exp Rheumatol 2010; 28 (Suppl. 60): S27-30.
8. ZHAO C, YANG P, HE H et al.: S-antigen specific T helper type 1 response is present in Behçet's disease. Mol Vis 2008; 14: 1456-64.
9. DALGHOUS AM, FREYSDOTTIR J, FORTUNE F: Expression of cytokines, chemokines, and chemokine receptors in oral ulcers of patients with Behçet's disease (BD) and recurrent aphthous stomatitis is Thl-associated, although Th2-association is also observed in patients with BD. Scand J Rheumatol 2006; 35: 472-5. (Pubitemid 47215715)
10. MELIKOGLU M, UYSAL S, KRUEGER JG et al.: Characterization of the divergent woundhealing responses occurring in the pathergy reaction and normal healthy volunteers. J Immunol 2006; 177:6415-21. (Pubitemid 44628860)
11. AKMAN-DEMIR G, TÜZÜN E, IÇÖZ S et al.: Interleukin-6 in neuro-Behçet's disease: association with disease subsets and long-term outcome, Cytokine 2008; 44: 373-6.
12. HAMZAOUI K, HOUMAN H, HAMZAOUI A: ReGÜLatory T cells in cerebrospinal fluid from Behçet's disease with neurological manifestations. J Neuroimmunol 2007; 187: 201-4.
13. HAMZAOUI K, BORHANI HAGHIGHI A, BEN GHORBEL I, HOUMAN H: RORC and Foxp3 axis in cerebrospinal fluid of patients with Neuro-Behçet's Disease. J Neuroimmunol 2011;233:249-53.
14. ABBAS AK, MURPHY KM, SHER Afunctional diversity of helper T lymphocytes. Nature 1996;383:787-93. (Pubitemid 26372655)
15. GLIMCHER LH, MURPHY KM: Lineage commitment in the immune system: the T helper lymphocyte grows up. Genes Dev 2000; 14: 1693-711. (Pubitemid 30602989)
16. ZHOU L, CHONG MM, LITTMAN DR: Plasticity of CD4+ T cell lineage differentiation. Immunity 2009; 30: 646-55.
17. MOSMANN TR, CHERWINSKI H, BOND MW, GIEDLIN MA, COFFMAN RL: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986; 136: 2348-57. (Pubitemid 16136806)
18. CURTIS MM, WAY SS: Interleukin-17 in host defence against bacterial, mycobacterial and fungal pathogens. Immunology 2009; 126: 177-85.
19. SZABO SJ, KIM ST, COSTA GL, ZHANG X, FATHMAN CG, GLIMCHER LH: A novel transcription factor, T-bet, directs Thl lineage commitment. Cell 2000; 100: 655-69.
20. ZHENG W, FLAVELL RA: The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997; 89: 587-96. (Pubitemid 27511769)
21. IVANOV II, FRUTOS RDE, MANEL N et al.: Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of small intestin. Cell Host Microbe 2008; 4: 337-49.
22. SAKAGUCHI S, SAKAGUCHI N, ASANO M, ITOH M, TODA M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of selftolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-64.
23. FONTENOT JD, GAVIN MA, RUDENSKY AY: Foxp3 programs the development and function of CD4+CD25+ reGÜLatory T cells. Nat Immunol 2003; 4: 330-6. (Pubitemid 36432314)
24. COLLISON LW, WORKMAN CI, KUO IT et al.: The inhibitory cytokine IL-35 contributes to reGÜLatory T-cell function. Nature 2007; 450: 566-9. (Pubitemid 350190247)
25. NIEDBALA W, WEI XQ, CAI B et al.: IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of reGÜLatory T cells and suppression of Thl 7 cells. Eur J Immunol 2007; 37: 3021-9. (Pubitemid 350131282)
26. WILLIAMS LM, RUDENSKY AY: Maintenance of the Foxp3-dependent developmental program in mature reGÜLatory T cells requires continued expression of Foxp3. Nat Immunol 2007; 8: 277-84. (Pubitemid 46745377)
27. YANG J, YANG M, HTUT TM et al.: Epstein- Barr virus-induced gene 3 negatively reGÜLates IL-17, IL-22 and RORgamma t. Eur J Immunol 2008; 38: 1204-14.
28. KOLLS JK, LINDEN A: Interleukin-17 family members and inflammation. Immunity 2004; 21:467-76. (Pubitemid 39370503)
29. HOYER KK, DOOMS H, BARRON L, ABBAS AK: Interleukin-2 in the development and control of inflammatory disease. Immunol Rev 2008; 226: 19-28.
30. VELDHOEN M, HOCKING RJ, ATKINS CJ, LOCKSLEY RM, STOCKINGER B: TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006; 24: 179-89. (Pubitemid 43214587)
31. DEKNUYDT F, BIOLEY G, VALMORI D, AYYOUB M: IL-lbeta and IL-2 convert human Treg into T(H)17 cells. Clin Immunol 2009; 131:298-307.
32. AYYOUB M, DEKNUYDT F, RAIMBAUD I et al.: Human memory FOXP3+ Tregs secrete IL-17 ex vivo and constitutively express the T(H)17 lineage-specific transcription factor RORgamma t. Proc Natl Acad Sci USA 2009; 106: 8635-40.
33. DEKNUYDT F, SCOTET E, BONNEVILLE M: Modulation of inflammation through IL-17 production by gammadelta T cells: mandatory in the mouse, dispensable in humans? Immunol Lett 2009; 127: 8-12.
34. MANGAN PR, HARRINGTON LE, O'QUINN DB et al.: Transforming growth factor-beta induces development of the T(H)17 lineage, Nature 2006; 441: 231-4.
35. EVANS HG, SUDDASON T, JACKSON I, TAAMS LS, LORD GM: Optimal induction of T helper 17 cells in humans requires T cell receptor ligation in the context of Toll-like receptor-activated monocytes, Proc Natl AcadSci USA 2007; 104: 17034-9. (Pubitemid 350210986)
36. ACOSTA-RODRIGUEZ EV, RIVINO L, GEGINAT J et al.: Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007; 8: 639-46. (Pubitemid 46785128)
37. V. TOSELLO, ODUNSI K, SOULEIMANIAN NE et al.: Differential expression of CCR7 defines two distinct subsets of human memory CD4(+)CD25(+) Tregs. Clin Immunol 2008; 126: 291-302.
38. MARSHAK-ROTHSTEIN A: Toll-like receptors in systemic autoimmune disease. Nat Rev Immunol 2006; 6: 823-35. (Pubitemid 44631651)
39. YANG L, ANDERSON DE, BAECHER-ALLAN C et al.: IL-21 and TGF-beta are required for differentiation of human T(H)17 cells. Nature 2008; 454: 350-2.
40. KRYCZEK I, WEI S, VATAN L et al.: Cutting edge: opposite effects of IL-1 and IL-2 on the reGÜLation of IL-17+ T cell pool 1L-1 subverts IL-2-mediated suppression. J Immunol 2007; 179: 1423-6.
41. Dinarello CA: Blocking IL-1 in systemic inflammation. J Exp Med 2005; 201: 1355-9. (Pubitemid 40664079)
42. WEI G, WEI L, ZHU J et al.: Global mapping of H3K4me3 and H3K27me3 reveals specificity and plasticity in lineage fate determination of differentiating CD4 T cells. Immunity 2009; 30: 155-67.
43. CORNELISSEN F, DOMINGO PA, REIJMERS RM, CUPEDO T: Activation and effector functions of human RORC+ innate lymphoid cells. Curr Opin Immunol 2011; 23: 361-7.
44. DIRESKENELI H: Autoimmunity vs autoinflammation in Behçet's disease: do we oversimplify a complex disorder? Rheumatology (Oxford) 2006; 45: 1461-5. (Pubitemid 44817050)
45. YAVUZ S, ELBIR Y, TULUNAY A, EKSIOGLUDEMIRALP E, DIRESKENELI H: Differential expression of toll-like receptor 6 on granulocytes and monocytes implicates the role of microorganisms in Behçet's disease etiopathogenesis. Rheumatol Int 2008; 28:401-6. (Pubitemid 351629487)
46. HAMZAOUI K, HAMZAOUI A, GUEMIRA F, BESSIOU M, HAMZA M, AYED K: Cytokine profile in Behçet's disease patients. Relationship with disease activity. Scand J Rheumatol 2002; 31: 205-10. (Pubitemid 34971876)
47. AKMAN A, SALLAKCI N, COSKUN M et al.: TNF-alpha gene 1031 T/C polymorphism in Turkish patients with Behçet's disease. Br J Dermatol 2006; 155:350-6. (Pubitemid 44050569)
48. HAMZAOUI K, HOUMAN H, BEN DHIFALLAH I, KAMOUN M, HAMZAOUI A: Serum BAFF levels and skin mRNA expression in patients with Behçet's disease. Clin Exp Rheumatol 2008; 26 (Suppl. 50): S64-71.
49. HAMZAOUI A, CHELBI H, SASSI FH, HAMZAOUI K: Release of B cell-activating factor of the TNF family in bronchoalveolar lavage from Behçet's disease with pulmonary involvement. Oxid Med Cell Longev 2010; 3: 122-8.
50. KAMOUN M, CHELBI H, HOUMAN MH, LACHEB J, HAMZAOUI K: Tumor necrosis factor gene polymorphisms in Tunisian patients with Behçet's disease. Hum Immunol 2007;68:201-5 (Pubitemid 46356652)
51. SHIM J, BYUN HO, LEE YD, LEE ES, SOHN S: Interleukin-6 small interfering RNA improved the herpes simplex virus-induced systemic inflammation in vivo Behçet's disease- like mouse model. Gene Ther 2009; 16: 415-25.
52. CHOI B, HWANG Y, KWON HJ et al.: Tumor necrosis factor alpha small interfering RNA decreases herpes simplex virus-induced inflammation in a mouse model. J Dermatol Sci 2008; 52: 87-97.
53. FAOUR WH, MANCINI A, HE QW, DI BATTISTA JA: T-cell-derived interleukin-17 reGÜLates the level and stability of cyclooxygenase- 2(COX-2) mRNA through restricted activation of the p38 mitogen-activated protein kinase cascade: role of distal sequences in the 3'-untranslated region of COX-2 mRNA. J Biol Chem 2003; 278: 26897-907. (Pubitemid 36876841)
54. YANG J, CHU Y, YANG X et al.: Thl7 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum 2009; 60: 1472-83.
55. HAMZAOUI K, BOUALI E, GHORBEL I, KHANFIR M, HOUMAN H, HAMZAOUI A: Expression of Th-17 and RORgammat mRNA in Behçet's Disease. Med Sci Monit 2011: 17: CR227-234.
56. ZHOU L, LOPES JE, MARK MW et al.: TGFbeta- induced Foxp3 inhibits T(H)17 cell differentiation by antagonizing RORgammat function. Nature 2008; 453: 236-40. (Pubitemid 351667978)
57. SARUHAN-DIRESKENELI G, YENTOR SP, AKMAN-DEMIR G, ISIK N, Serdaroǧlu P: Cytokines and chemokines in neuro-Behfet's disease compared to multiple sclerosis and other neurological diseases. J Neuroimmunol 2003; 145: 127-34. (Pubitemid 37485973)